Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Publication schedule for Oriola Corporation's financial reporting in 2023

Oriola Corporation Stock Exchange Release 18 October 2022 at 09.45 a.m. Publication schedule for Oriola Corporation's financial reporting in 2023 Oriola Corporation will publish its financial statements release for 1 January - 31 December 2022 on Thursday, 16 February 2023. The publication dates of the financial reports in 2023 are as follows: Interim Report 1-3/2023 on Thursday, 27 April 2023 Half year financial report 1-6/2023 Friday, 21 July 2023 Interim Report 1-9/2023 on Friday, 27 October 2023 Oriola Corporation's Annual General Meeting will be held on Tuesday, 21

Cereno Scientific expands patent protection for drug candidate CS1 through its second patent family

Cereno Scientific (XSAT: CRNO B) today announced that drug candidate CS1’s second patent family has obtained patents in Israel and in Malaysia, respectively. This strengthens and broadens the intellectual property rights (IPR) for Cereno’s Phase II drug candidate CS1, which is being developed for the treatment of rare disease pulmonary arterial hypertension (PAH).“The development of our lead drug candidate CS1 is currently progressing in a Phase II study with active patient recruitment across sites in the US. I am pleased to, in parallel, have news related to CS1’s growing patent portfolio

InCoax secures additional order of USD 3.1 million (SEK 34.7 million) from the US based Fiber/LAN operator

InCoax has received additional order from the US based Fiber/LAN operator with which InCoax signed a framework agreement in the autumn of 2021 for the purchase of InCoax system for fiber extension. The order, which is the largest in InCoax history, amounts to USD 3.1 million (SEK 34.7 million) and will be delivered and invoiced continuously during 2022 and all of 2023.InCoax and the operator have for some time held discussions about a more long-term and joint planning to ensure the expansion that the operator intends to carry out with the InCoax solution. This has resulted in a larger order

Inhalation Research Services receives revised order with increased payment from US pharma company

(Stockholm 18 October 2022) Inhalation Research Services (IRS) has received a revised order increasing the amount that it will be paid by a US pharma company. The original order, communicated on 18 July 2022, was for 136,000 Euro. This has now been raised to 151,000 Euro as additional steps within the research project have been contracted out to IRS by the client.ISAB’s world-class expertise in inhalation, and its high-precision IPL (Isolated Perfused Lung) ex vivo method, were decisive in the client’s choice of IRS for research into a new repurposed drug being reformulated for

BioStock: BrainCool’s CEO on FDA approval of Cooral

BrainCool has reached an important milestone in its oncology project with the product Cooral System. The company has now received market approval from the US Food and Drug Administration for counteracting chemotherapy-induced oral mucositis, a common and serious side effect of cancer treatment. BioStock contacted BrainCool’s CEO Martin Waleij for a comment on the significance of the FDA’s announcement.Read the full interview with Martin Waleij at biostock.se: https://www.biostock.se/en/2022/10/braincools-ceo-on-fda-approval-of-cooral/ This is a press release from BioStock - Connecting

Doing My Own Research: Why Don’t Americans Use Health Apps but Follow the Advice They Find Online?

From medical institutions to tech corporations to health startups to investors – everyone in the health field has turned their focus toward digital health during the pandemic. While the number of virtual visits to the doctor’s office is decreasing after the lockdowns ended, the field is still going strong, which is confirmed by the fact that the investments in the industry nearly doubled in 2020 .With all this excitement around the industry, what are the

TOMRA: Invitation to Q3 2022 Presentation

TOMRA's third quarter 2022 results will be released Friday 21 October 2022. President & CEO Tove Andersen and CFO Eva Sagemo will present the results at 08:00 CEST (UTC+2). The presentation will be sent via live webcast. Questions to the speakers can be directed using the Q&A-tool embedded in the webcast and will be addressed towards the end of the presentation. A recorded version of the webcast will be available shortly after the webcast has concluded. Link to the webcast will be available on www.tomra.com (Investor Relations section). https://www.tomra.com/en/investor-

GlobalConnect successfully raised EUR 1 billion in new ESG linked financing, enabling sustainable growth

GlobalConnect Group has raised additional financing to fund its ambitious growth plan, as a consortium of Nordic and international banks and financial institutions committed additional Senior Debt Facilities of a total of EUR 1 billion. Sustainability incentives were also introduced with the new facilities, with the effect of lowered interest rate margin upon meeting targets for predetermined sustainability KPIs.In June 2021, GlobalConnect completed an extensive refinancing where a new Senior Debt Facility structure of €2,700m was committed from a complementary group of leading Nordic and

BioArctic presents Nomination Committee

Stockholm, Sweden, October 18, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) Annual General Meeting on May 5, 2022, adopted an instruction regarding the appointment of the Nomination Committee. Pursuant to this instruction the company shall have a Nomination Committee comprising one representative for each of the three principal shareholders in terms of votes, based on the information received from Euroclear Sweden AB on the last banking day in September 2022, as well as the Chairman of the Board (convener).September 30, 2022, the three largest shareholders were Demban AB,

JM acquiring buildings rights for residential development in Gothenburg

JM has acquired building rights for the development of approximately 130 residential units located in the Eriksberg district in Gothenburg. The acquisition amounts to approximately SEK 160 million, with occupancy and payment in Q4 2022.The acquisition will be reported within the JM Residential Sweden business segment in Q4 2022.   The property has a detailed plan that has gained final approval and is judged to allow the development of approximately 130 residential units as well as commercial premises on the bottom floor. Due to the development work in connection with the property,

Invitation to Rottneros’ interim report, Q3 2022

The interim report for the third quarter 2022 will be published on 27 July 2022, at 8.00 CET, and is followed by a webcast live at 10.00 CET the same day.All participants can follow the presentation via the web link: Rottneros - Q3 presentation 2022   Questions can be asked via the link in advance or during the presentation. You can also watch the presentation afterwards via Rottneros'  Youtube channel  and website: https://www.rottneros.com/investors/presentations/  The

Asetek Liquid Cooling Technology Advances Overclocking Capability In EVGA’s New CLX Closed Loop CPU Cooler Series

Aalborg, Denmark – October 18, 2022 –– Asetek, innovator of gaming hardware for next-level immersive gaming experiences and the creator of the all-in-one liquid cooler, today announced its liquid cooling technology is powering EVGA’s highest-performing CPU cooler series to date – the EVGA CLX. Asetek’s advanced liquid cooling technology enables extreme performance with minimal noise, providing gamers and enthusiasts targeted cooling of CPUs, outstanding gameplay, and greater overclocking potential. “EVGA and Asetek worked together to create a new cooler series to maximize heat transfer

Loomis AB to publish Interim report on October 28, 2022

Loomis AB will publish the Interim report January-September 2022 on Friday October 28, at 8:00 a.m. (CEST). Agenda 8.00 a.m. (CEST) - Report releaseThe report will be sent as a press release from Cision (www.cision.se) and will automatically be published on www.loomis.com when released. 8:30 a.m. (CEST) - Presentation slides availableFor presentation slides, go to www.loomis.com and choose “Financial presentation”. 9.00 a.m. (CEST) – Telephone conference and audio castAnalysts and media are invited to participate in a telephone conference at 9:00 a.m. CEST where Loomis

Stable growth in a changing environment

· Rental income increased to SEK 921 million (897) · Income from property management increased to SEK 528 million (499) · Profit for the period increased to SEK 3,446 million (1,237) · Property portfolio amounted to SEK 27,002 (26,031) · Earnings per share totalled SEK 28.46 (10.30) · Positive net lettings in every quarter in both business areas offices and industrial/logistics · Platzer and Bockasjö let additional 13,300 sq. m. in Sörred Logistikpark · Completion of property disposals in Gamlestadens Fabriker and in phase 1 of Södra Änggården · P-G Persson to step

Essity’s subsidiary Vinda publish the interim report for the third quarter 2022

Essity’s subsidiary Vinda International Holdings Ltd today published the interim report for the third quarter 2022.  Link to the full report: http://www.vinda.com/upload/files/20221018/0802r68l20.pdfEssity is the majority shareholder of Vinda and owns 52% of the company. Vinda is listed on the Hong Kong Stock Exchange. Essity consolidates Vinda and in 2021 Vinda’s net sales accounted for approximately 17% of Essity’s net sales.  Essity’s Interim Report for the third quarter 2022 will be published on October 27, 2022, at approximately 07:00 CET.

Faron Pharmaceuticals Presents Results from PD-1 Blockade Refractory Melanoma Cohort of MATINS Trial at 19th International Congress of The Society for Melanoma Research

Faron Pharmaceuticals Ltd. (“Faron or Company”)   Faron Pharmaceuticals Presents Results from PD-1 Blockade Refractory Melanoma Cohort of MATINS Trial at 19th International Congress of The Society for Melanoma Research   · 100% overall survival at 12-months in PD-1 blockade refractory melanoma patients who experienced clinical benefit from bexmarilimab · Patients with cold tumors, defined by low baseline levels of pro-inflammatory cytokines, were more likely to experience clinical benefit following treatment with bexmarilimab · Patients who experienced clinical

Norse Atlantic Airways agrees terms for the sublease of a fifth Boeing 787-8 aircraft

Norse Atlantic Airways has signed a term sheet for sublease of a fifth aircraft, a Boeing 787-8, for a total lease period of 18 months. The agreement will increase total cash profit during the sublease period and is in addition to the previously announced four aircraft that have been subleased. The aircraft is expected to be delivered to the sub-lessee before year end with a lease period of 18 months.Norse has taken delivery of 13 of a total fleet of 15 Boeing 787 Dreamliners. All 15 aircraft are on long-term flexible lease terms agreed during 2021 when lease rates were at historical low

SAS PRESENTS WINTER TRAFFIC PROGRAM

SAS continues to open new routes and schedules more flights to popular destinations. During the coming winter, SAS will operate more than 170 routes to 90 destinations.SAS continues to see a general increase in demand for travel both to classic ski destinations and warmer holiday destinations. The winter program offers two new routes to Tenerife from Gothenburg and Oslo, with service on Sundays. More capacity will be added from Stockholm and Copenhagen to Gran Canaria and Tenerife on Saturdays and Sundays. In addition, SAS is returning to popular winter destinations such as Miami, Sälen/

Balder´s nomination committee ahead of the 2023 Annual General Meeting

Balder’s Annual General Meeting on 12 May 2022 resolved that the nomination committee should be composed of one representative for each of the two largest owners or ownership spheres, together with Lars Rasin, who represents the other shareholders. The names of the other two members and the owners they represent, shall be published not later than six months before the Annual General Meeting 2023 and shall be based on the known ownership immediately prior to publication. In accordance with the resolution, the following nomination committee has been established, based on the ownership as of

Hexagon Purus ASA: Invitation to presentation of third quarter 2022 results

Hexagon Purus ASA’s third quarter results 2022 will be released on 1 November 2022, 07:00 CET. Morten Holum (CEO) and Dilip Warrier (CFO) will present the results at 08:30 CET and the presentation will be broadcasted live via https://hexagonpurus.kg5.no/. The presentation will be held in English and will be virtual. A recording of the presentation will be made available on www.hexagonpurus.com. For more information: Mathias Meidell, Investor Relations Director, Hexagon Purus ASATelephone: +47 909 82 242 | mathias.meidell@hexagonpurus.com Dilip Warrier, CFO, Hexagon Purus

UPM’s President and CEO Jussi Pesonen will retire during 2024

UPM-Kymmene Corporation        Stock Exchange Release (Changes board/management/auditors)        18 October 2022 at 09:00 EEST UPM’s President and CEO Jussi Pesonen will retire during 2024 In accordance with the terms of his service contract, UPM’s President and CEO Jussi Pesonen has announced that he will exercise his right to retire from UPM during 2024. "In 2024 I will have served UPM as President and CEO for 20 years and spent a total of 37 years with the company. The announced timetable aims to secure the success of the strategic growth initiatives as well as business

Invitation to presentation of LMK Group’s Q3 2022 report

LMK Group will publish its Q3 2022 report on 1 November 2022 at 07:45 CET. In connection with this, LMK Group invites investors, analysts and media to a conference call and webcast on the same day at 09:00 CET.The presentation will be held in English by CEO Walker Kinman and CFO Erik Bergman and will conclude with a Q&A session. Questions can be asked on the telephone conference call or in written form through the webcast. No preregistration is needed. Date and time1 November 2022 at 09:00 CET Webcasthttps://ir.financialhearings.com/lmk-group-q3-2022 Phone numberTo

Share buy-backs in Telia Company during week 41 2022

Telia Company AB (publ) (LEI code 213800FSR9RNDUOTXO25) has repurchased own shares (ISIN: SE0000667925) as specified in the table below. The share buy-backs form part of the SEK 5.4 billion share buy-back program that Telia Company announced on June 1, 2022 . The share buy-back program is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 (“MAR”) and the Commission Delegated Regulation (EU) No 2016/1052 (the “Safe Harbour Regulation”)

There are no items matching the current filter
There are no more items matching the current filter
Back to top